Tickers

1. Composite Trajectory Verdict

Given AMRX's pharmaceutical manufacturing and distribution model with significant working capital needs, ongoing litigation settlements, and debt-financed growth, all three statements carry roughly equal weight: the income statement shows operating momentum, the cash flow statement reveals the cash cost of that momentum, and the balance sheet reflects the funding strain.

Composite Trajectory: Mixed

Earnings are improving decisively: annual net revenue rose 8.0% to $3.019B with operating income up 58.1% to $394.1M and net income swinging to $127.9M from a $73.9M loss (10-K 2025, Consolidated Statements of Operations). Quarterly trends reinforce this: Q2 2026 net revenue grew 9.9% YoY to $796.2M with operating income up 16.5% to $129.8M (10-Q 2026-06-30, MD&A). Gross margin expanded from 36.5% to 36.9% annually and from 38.2% to 43.1% over the first six months of 2026 (10-K 2025; 10-Q 2026-06-30). Cash generation, however, deteriorated sharply in H1 2026: operating cash flow swung to -$48.0M from +$91.2M a year earlier, driven by $35.9M opioid settlement payments, $38.8M TRA payments, unfavorable receivables, and inventory builds (10-Q 2026-06-30, Cash Flows). The balance sheet shows cash falling 55% in six months to $127.6M while the revolver was drawn for $100M (10-Q 2026-06-30, Balance Sheets). Leverage increased and a $375M Kashiv acquisition looms.

2. Red Flags

• Operating cash flow reversed to -$48.0M in H1 2026 from +$91.2M in H1 2025 despite net income rising 145% to $147.6M (10-Q 2026-06-30, Cash Flows; Consolidated Statements of Operations).
• Cash and equivalents dropped from $282.0M at 2025 year-end to $127.6M at June 30, 2026, a $154.4M decline in six months (10-K 2025, Balance Sheet; 10-Q 2026-06-30, Balance Sheet).
• Revolving credit facility drawn $100M at June 30, 2026 versus $0 at December 31, 2025 (10-Q 2026-06-30, Balance Sheet).
• SG&A growing faster than revenue: +19.7% vs +9.9% in Q2 2026; +18.6% vs +7.0% in H1 2026 (10-Q 2026-06-30, MD&A).
• $35.9M opioid settlement and $38.8M TRA payments in H1 2026; $97.6M further opioid payments expected through 2034 (10-Q 2026-06-30, Liquidity and Capital Resources).
• Kashiv acquisition requires $375M cash at closing (expected Q3 2026) plus integration costs; $150M already borrowed on revolver in August 2026 for this purpose (10-Q 2026-06-30, Overview; Liquidity and Capital Resources).
• India facility water damage (July 2026) estimated at $10-15M direct losses plus ~$20M lost pre-tax profit in H2 2026 (10-Q 2026-06-30, Overview).
• Section 232 tariff investigation ongoing; potential 100% tariffs on certain branded FDF/API (10-Q 2026-06-30, Trade Policy and Tariffs).
• Stockholders' deficiency persisted at -$70.8M as of December 31, 2025 (10-K 2025, Balance Sheet).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Revenue growth is consistent and broadening: FY2025 net revenue rose 8.0% to $3.019B; Q2 2026 rose 9.9% to $796.2M; H1 2026 rose 7.0% to $1.519B (10-K 2025; 10-Q 2026-06-30). All three segments contributed in FY2025; in H1 2026 Affordable Medicines (+7.7%) and Specialty (+19.6%) grew while AvKARE declined 3.7% due to low-margin distribution exits (10-Q 2026-06-30). Gross margin expanded annually (36.5% to 36.9%) and accelerated in H1 2026 (38.2% to 43.1%) driven by favorable mix, lower amortization, and operating leverage (10-K 2025; 10-Q 2026-06-30). Operating income surged 58.1% annually to $394.1M and rose 28.3% in H1 2026 to $271.5M (10-K 2025; 10-Q 2026-06-30). Net income swung from -$73.9M to +$127.9M annually and jumped 145% in H1 2026 to $147.6M (10-K 2025; 10-Q 2026-06-30). R&D declined modestly in each period; SG&A growth outpaced revenue in recent quarters but operating leverage still held.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Annual operating cash flow improved 15.2% to $340.0M in FY2025 (10-K 2025). However, H1 2026 operating cash flow collapsed to -$48.0M from +$91.2M in H1 2025 (10-Q 2026-06-30). The filing attributes the swing to working capital outflows: $35.9M opioid settlement payments, $38.8M TRA payments, unfavorable trade receivables collections, and inventory increases to support growth initiatives (10-Q 2026-06-30, Cash Flows). Investing outflows doubled to -$144.5M in H1 2026 from -$44.3M, primarily due to a $75.0M upfront product-rights payment and higher capex deposits (10-Q 2026-06-30). Financing flipped to +$20.3M from -$80.9M on net debt inflows (10-Q 2026-06-30). Net cash decreased $173.3M in H1 2026 versus $34.7M in H1 2025 (10-Q 2026-06-30). The divergence between rising net income and falling operating cash is pronounced.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets grew modestly to $3.776B at June 30, 2026 from $3.678B at December 31, 2025 (10-Q 2026-06-30; 10-K 2025). Receivables rose 14% to $1.021B and inventory 12% to $678M, while cash fell 55% to $127.6M (10-Q 2026-06-30; 10-K 2025). The revolver was drawn for $100M (zero at year-end 2025) and long-term debt stood at $2.565B (10-Q 2026-06-30; 10-K 2025). Current liabilities declined slightly as accounts payable fell to $743M from $817M (10-Q 2026-06-30; 10-K 2025). Redeemable non-controlling interests increased to $77.3M from $65.0M (10-Q 2026-06-30; 10-K 2025). Stockholders' deficiency improved annually from -$109.3M to -$70.8M but quarterly equity detail is not fully comparable in the provided XBRL (10-K 2025; 10-Q 2026-06-30). Leverage increased with cash drawdown and revolver usage ahead of the Kashiv acquisition.

6. Data Gaps

• Quarterly balance sheet equity detail (APIC, retained earnings, AOCI) for June 30, 2026 to assess deficit movement since year-end.
• Full-year 2026 capital expenditure actuals versus the $110M (10-K) / $150M (10-Q) estimates.
• Post-closing balance sheet impact of Kashiv acquisition (expected Q3 2026).
• Detailed debt maturity profile beyond the contractual obligations table in the 10-K (which shows $294M due in <1 year as of Dec 31, 2025).
• Q3 2026 and Q4 2026 results to see if H1 cash flow deterioration persists or reverses.
• Insurance recovery estimates for India facility water damage.
• Quantified impact of potential Section 232 tariffs on branded products.